Thoracic SMARCA4-deficient tumors were first included in the World Health Organization’s (WHO's) 2015 classification of thoracic neoplasms as a distinct category to facilitate tailored therapeutic approaches [6]. This evidence concerns the gene SMARCA4 and neoplasm of thorax.